Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels

Slides:

Advertisements

Similar presentations

The efficacy of ‘Basal supported Oral Therapy ’ with ‘Sitagliptin’ in Japanese type 2 diabetes patients: Yoshihiko Suzuki HDC Atlas Clinic,

Advertisements

7-4 Lesson 7-4 Example 1 Use the bar graph “Championship Series” to compare data. How many runs did the Cougars score in Games 4 and 5 combined? Example.

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin.

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Barriers to Diabetes Control Mark E. Molitch, MD.

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Epidemiology and Diagnosis A Practical Guide to Therapy Monotherapy Combination Therapy Add ons.

WEEK 1 You have 10 seconds to name…

SGLT2 inhibitors Ian Gallen Consultant Community Diabetologist

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

Fig. 1. Study flow chart. Group A: intensifying oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to.

Copyright © 2015 by the American Osteopathic Association.

Fig. 1. Concentric left ventricular hypertrophy by echocardiography

Taieb V, et al. Value Health Nov;18(7):A598.

An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials Obes Facts 2012;5:485–494 - DOI: / Fig. 1. Occurrence of two.

Copyright © 2005 American Medical Association. All rights reserved.

Adding rosiglitazone to metformin in patients with type 2 diabetes: Effect on diabetes control and metabolic parameters Hussein Raef, Abdulraof Al-Mahfouz,

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

Figure 1. Consort flow diagram.

Copyright © 2002 American Medical Association. All rights reserved.

(B.P :51) ( B:P52 ).

Placebo Metformin ***p < vs placebo

Empagliflozin (Jardiance®)

End point Muraglitazar 5 mg plus metformin (n=569)

MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Updates on Emerging GLP-1 Receptor Agonists

Global Projections for Diabetes:

EFFICACY AND MECHANISM

Figure 4 Effect of dapagliflozin on HbA1c and body weight

SGLT2 Inhibitors in Phase 3 Trials

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Early and Intensive T2D Management:

Antidepressant Therapy in Patients Undergoing Coronary Artery Bypass Grafting: The MOTIV-CABG Trial Sidney Chocron, MD, PhD, Pierre Vandel, MD, PhD,

Differences in the glycated hemoglobin (HbA1c) levels.

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

The Role of the Kidney in Glucose Control

Selected efficacy and safety parameters.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS.

Illustration of the causal inference scheme.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

A Preliminary Assessment of the Benefits of the Addition of Botulinum Toxin A to a Conventional Therapy Program on the Function of People With Longstanding.

Volume 6, Pages (December 2018)

Ok, we know they are great, but can we add and subtract them?

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Fig. 3. (A) Least-squares (LS) mean difference in glycosylated hemoglobin (HbA1c) from baseline, and (B) LS mean difference in HbA1c from baseline over.

Fig. 2. Proinflammatory response of macrophages may exacerbate mitochondrial dysfunction in adipocytes. In addition to the primary mitochondrial dysfunction.

Change in markers of glycometabolism and cardiovascular risk profile.

Interaction of updated mean serial HbA1c and serum triglyceride levels with sensory peripheral neuropathy over 7 years in 151 type 2 diabetic participants.

Types of Errors And Error Analysis.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

(A) Hemoglobin A1c (HbA1c) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (B) Urinary albumin to creatinine.

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

Fig. 2. Change in IPSS scores as a measure of treatment effectiveness

Fig. 2. Graph showing differences in hemoglobin concentrations at 6 weeks after surgery compared to those at the preoperative assessment (Pre–6 wk), immediately.

Effect of empagliflozin on efficacy parameters at week 18.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.

Mean BP by visit - all patients

Fig. 3. Differences in the prevalence of albuminuria after comorbidity stratification. (A) Obesity defined by a body mass index ≥25 kg/m2, (B) central.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Presentation transcript:

Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels. Changes in the HbA1c levels during acarbose add-on or metformin-switch therapy (A, baseline to week 16) and metformin, sitagliptin, and acarbose triple combination therapy (B, week 16 to 24). The mean±standard error values of the HbA1c levels (%) are plotted in line graphs with ‘a’ demonstrating P<0.05 compared to the HbA1c level in the Met+Sita group. The changes in the HbA1c levels (%) from the baseline to week 16 and from week 16 to 24 are plotted in the bar graphs. The between-group differences in the changes in the HbA1c from the baseline to week 16 and from week 16 to 24 were assessed by analysis of covariance using baseline HbA1c as a covariate. Met+Sita, the group treated with metformin, sitagliptin, and acarbose placebo; Met+Sita+Acarb, the group treated with metformin, sitagliptin, and acarbose; Sita+Acarb, the group treated with metformin placebo, sitagliptin and acarbose. aP<0.05 compared to baseline, bP<0.05 compared to the HbA1c change in the Met+Sita group. Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels. Changes in the HbA1c levels during acarbose add-on or metformin- switch therapy (A, baseline to week 16) and metformin, sitagliptin, and acarbose triple combination therapy (B, week 16 to 24). The mean±standard error values of the… Diabetes Metab J. 2019 Jun;43(3):287-301. https://doi.org/10.4093/dmj.2018.0054